Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19

NCT ID: NCT04363047

Last Updated: 2024-05-08

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Total Enrollment: 125 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-10-01
• Study Completion Date: 2026-07-31

Brief Summary

A team at the University of Manchester are developing a test that tcould be helpful in detecting immunity to the Coronavirus (which causes the COVID-19 disease) in participants with inflammatory arthritis. It is based on a flu assay has already developed; the team will replace the flu antigen with a Coronavirus antigen to see if it is effective.

This project aims to develop a test to see if people who have had the virus have developed immunity to it. This could help to predict who might or might not get the disease a second time, who should stay at home to be protected from potential infection or who will not develop any symptoms, even if exposed to the virus.

When vaccination trials against the Coronavirus will be launched, this test could also help to see if the vaccine is effective.

Conditions

SARS Virus

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Healthy Volunteers

These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study.

We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.

We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms).

40ml blood sample

Intervention Type: OTHER

We'll be collecting cells, DNA and serum.

Rheumatoid Arthritis

These people will have already provided at least one sample as part of the BRAGGSS Study.

We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.

We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms).

40ml blood sample

Intervention Type: OTHER

We'll be collecting cells, DNA and serum.

Interventions

40ml blood sample

We'll be collecting cells, DNA and serum.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Has previously taken part in either the BRAGGSS or National Repository Healthy Volunteer Study
• Has agreed to be contacted abut future research projects
• Has previously provided a blood sample for either the BRAGGSS or National Repository Healthy Volunteer Study
• Is willing to complete the informed consent form, registration slip, questionnaire and provide a 40ml blood sample
• Has a good written understanding of English

Exclusion Criteria

• Has not previously taken part in either the BRAGGSS or National Repository Healthy Volunteer Study
• Has not agreed to be contacted abut future research projects
• Has not previously provided a blood sample for either the BRAGGSS or National Repository Healthy Volunteer Study
• Is not willing to complete the informed consent form, registration slip, questionnaire and provide a 40ml blood sample
• Has not got a good written understanding of English

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Manchester

OTHER

Sponsor Role: lead

Responsible Party

Dr. Sebastien Viatte

Lecturer in Genetics

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Manchester

Manchester, Greater Manchester, United Kingdom

Countries

United Kingdom

Other Identifiers

282566

Identifier Type: -

Identifier Source: org_study_id